Skip to main
MGX

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Therapeutics Inc. is recognized for its innovative approach to genetic medicine, utilizing a proprietary metagenomics-derived genome editing toolbox that includes advanced systems like programmable nucleases and CRISPR-associated transposases. The company has demonstrated significant progress in its pipeline, achieving durable factor VIII (FVIII) levels of 80% over a 19-month period in preclinical models for disorders such as Hemophilia A, underscoring the effectiveness of its gene editing technology. The strategic focus on vivo gene editing for its wholly-owned pipeline, alongside pursuing technology out-licensing opportunities for ex vivo cell therapy, positions Metagenomi favorably for future growth and revenue potential.

Bears say

Metagenomi Therapeutics reported a net loss of $19.9 million in its 2Q25 financial results, translating to a loss of $0.54 per share. The company is also trading significantly below cash, highlighting potential upside; however, this position is overshadowed by substantial risks, including possible delays in clinical assessments and the failure to produce favorable data from key pipeline candidates. Furthermore, there is a looming concern regarding long-term dilution risk, contributing to a primarily negative outlook on the company's financial health and stock performance.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.